First AD

Second AD

Approaching Biomarker Testing and Frontline Maintenance Therapy for Advanced Ovarian Cancer

Video content above is prompted by the following:

How do you typically approach biomarker testing for advanced ovarian cancer?

When do you test and what type of testing do you perform?

Which biomarkers do you generally access (e.g., BRCA1/2, HRD, etc) and how do results help guide your treatment approach?

Briefly review frontline maintenance therapy options for advanced ovarian cancer and discuss key factors that drive your selection among available therapies.

 and HRD statuses influence your choice of maintenance therapy?

When may you opt for a combination (PARPi + bev) vs monotherapy approach?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Advancements in the Management of Gynecological Cancers: ESMO 2024 

Peer Exchange

Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between combination therapy (PARPi + bev) and monotherapy.